Incyte Presents Phase 1/2 Multidose Data For VGA039 (Latarcibart) At ISTH 2026, Showing 81% Median Reduction In Annualized Bleeding Rate Across All Von Willebrand Disease Types And Bleed Categories

Loading news article.

Incyte Presents Phase 1/2 Multidose Data For VGA039 (Latarcibart) At ISTH 2026, Showing 81% Median Reduction In Annualized Bleeding Rate Across All Von Willebrand Disease Types And Bleed Categories | WAPE

Incyte Presents Phase 1/2 Multidose Data For VGA039 (Latarcibart) At ISTH 2026, Showing 81% Median Reduction In Annualized Bleeding Rate Across All Von Willebrand Disease Types And Bleed Categories

Article summary

Related companies

Comments —